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Abstract 
Review on RHOA, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Keywords 
RhoA, Small Rho GTPase 
Identity 
Other names: ARH12, ARHA, H12, RHO12, 
RHOH12 
HGNC (Hugo): RHOA 
Location: 3p21.31 
Local order 
From the plasmatic membrane and cytoplasm. 
DNA/RNA 
Description 
The RhoA gene can be found on chromosome 3 at 
location: 49371585-49424530.  
This gene includes 5 exons. 
Transcription 
This gene has 6 transcripts (splice variants): 2031 bp 
(variant a); 961 bp (variant b); 889 bp (variant c); 
633 bp (variant d); 539 bp (variant e); 388 bp (variant 
f). 
Protein 
Description 
The RhoA protein encodes five alternative isoforms: 
variant a (193 amino acids), variant b (187 amino 
acids), variant c (90 amino acids), variant d (129 
amino acids) and variant e (86 amino acids). 
- RhoA structure: 
The available functional and structural data show 
that RHO-GTP-binding proteins are made-up of an 
effector domain, four separate guanosine phosphate 
binding regions that span the length of the core 
structure, a hypervariable region and a CAAX box 
motif (C: Cys; A: aliphatic residue; X: any residue). 
The effector domain (residues 26-45) changes 
conformation between the GTP bound and GDP 
bound states. All RHO proteins have conserved 
residues at Gly14, Thr19, Phe30 and Gln93 which 
are involved in binding, stabilization or regulation of 
GTP hydrolysis. The N-terminus region also 
contains switch 1 (residues 27-40) and switch 2 
(residues 59-78) regions which change conformation 
between GTP- and GDP-bound states and may 
facilitate changes in effector region required for 
binding to downstream targets. RhoA protein is 
target for several bacterial toxins, which modify key 
conserved amino acids involved in their regulation.  
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Schematic representation of the domains of RhoA. The available functional and structural data show that RHO-GTP-binding 
proteins are made-up of an effector domain, four separate guanosine phosphate binding regions that span the length of the core 
structure, a hypervariable region and a CAAX box motif (Lartey and López Bernal, 2009). 
 
These include Clostridium botulinum exoenzyme C3 
transferase, which modifies Asn41, and Toxin B, 
which acts on Thr37. The hypervariable region 
made-up of residues 173-189 is the region of most 
diversity between individual RHO family members. 
It may contain sites for palmitoylation and a 
polybasic region which can determine membrane 
association. The C-terminus of RhoA is essential for 
correct localization of the protein. RhoA is post-
translationally modified by prenylation of a 
conserved C-terminal cysteine followed by 
methylation and proteolytic removal of the last three 
amino acids. The prenyl group (geranylgeranyl) 
anchors the GTPase into membranes and this 
modification is essential for its stability, cell growth, 
transformation, and cytoskeletal organization. 
- RhoA activity regulation: 
Rho GTPases can be activated by intrinsic or 
extrinsic cues, setting off a signaling cascade 
(Etienne-Manneville and Hall, 2002). Rho GTPases 
behave as molecular switches that fluctuate between 
inactive and active states, two conformations that 
depend on the binding of either GDP or GTP to the 
GTPases, respectively (Bustelo et al., 2007). Two 
types of regulatory proteins control this cycling: 
guanine nucleotide-exchange factors (GEFs), which 
activate Rho GTPases by catalyzing the exchange of 
GDP for GTP (Rossman et al., 2005), and GTPase-
activating proteins (GAPs), which inactivate the 
GTPases by enhancing intrinsic GTP hydrolysis 
activity (Bos et al., 2007). There are over 80 GEFs 
and 70 GAPs for Rho GTPases, whose activity is 
tightly regulated and can be highly specific. RhoA 
can be sequestered in the cytoplasm by guanine 
nucleotide-dissociation inhibitors (GDIs), which 
bind prenylated GDP-bound Rho proteins (Garcia-
Mata et al., 2011), allowing translocation of Rho 
GTPases between membranes and cytosol. 
 
- RhoA effectors binding: 
To date, at least 21 proteins have been identified 
which directly interact with RhoA (ROCK1, 
ROCK2, PRKcA, PKN1, PKN2, RTKN1, RTKN2, 
RHPN1, RHPN2, KTN1, CIT, DIAPH1, KCNA2, 
ITRP1, PLD, MYBPH, PIP5K, FAK, BORG, MBS, 
GDIA).  
Some of these have been shown to contribute to 
specific responses downstream of RhoA. Similarly 
to GEFs and GAPs, effectors bind to Rho both 
through the Switch 1 and 2 regions, but the amino 
acids involved in interaction with each target differ. 
Expression 
RhoA protein is expressed in all tissues tested. RhoA 
expression in normal human tissues, embryonic 
tissues and stem cells. 
Localisation 
RhoA localizes predominantly in the plasmatic 
membrane and cytoplasm.  
Also, it localizes to cell-cell contacts and cell 
projections. 
Function 
RhoA is a protein involved in multiple cellular 
processes. 
- Role in actin organization:  
RhoA protein plays a central role in regulating cell 
shape, polarity and locomotion through their effects 
on actin polymerization, actomyosin contractility, 
cell adhesion, and microtubule dynamics. RhoA is 
believed to act primarily at the rear of migrating cells 
to promote detachment. 
RhoA directly stimulates actin polymerization 
through activiation of diaphanous-related formins 
(DRFs, also known as Dia proteins).  
These stimulate addition of actin monomers to the 
fast-growing end of actin filaments. DRFs act 
together with ROCKs to mediate Rho-induced stress 
fiber formation.  
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RhoA activity regulation. Rho GTPase activity is controlled by guanine nucleotide exchange factor (GEF), GTPase-activating 
protein (GAP) and guanine nucleotide dissociation inhibitor (GDI). GEF activates Rho GTPases by facilitating the release of GDP 
and the binding of GTP. GAP inactivates Rho GTPases by promoting hydrolysis of the bound GTP molecules, resulting in their 
quick change from the GTP-bound form to the GDP-bound form. GDI binds to C-terminal prenyl groups on some Rho proteins, 
maintaining them in the inactive state. Active Rho GTPases act on their downstream effector proteins, stimulating a variety of 
cellular processes (Chi et al., 2013). 
 
ROCK-mediated phosphorylation of LIMK and 
consequent inhibition of cofilin also contributes to 
the increase in actin filaments in response to Rho. 
In addition, ROCKs induce actomyosin-based 
contractility and phosphorylate several proteins 
involved in regulating myosins and other actin-
binding proteins.  
Actomyosin contractility is important in migrating 
cells for detachment of the rear. Microtubules are 
essential for determining cell polarity as well as for 
vesicular locomotion and intracellular transport.  
The concerted action of ROCK and Dia is essential 
for the regulation of cell polarity and organization of 
microtubules. ROCK phosphorylates TAU and 
MAP2, proteins that regulate microtubule stability. 
RhoA plays a key role in regulating the integrity of 
cell-extracellular matrix and cell-cell adhesions, the 
latter including both adherens junctions and tight 
junctions.  
Loss of cell-cell junctions is required form the 
migration of epithelial cells and may be regulated 
reciprocally by ROCKs and DRFs. Also, RhoA is 
localized to developing axons and growth cones, and 
this localization is mediated by an axonal targeting 
element located in the RhoA 3' untranslated region 
(UTR). Local RhoA translations regulate the 
neuronal cytoskeleton and identify a new mechanism 
for the regulation of RhoA signaling (Wu et al., 
2005). On the other hand, increasing expression of 
the transcription repressor, GCF2, can silence RhoA 
expression, leading to actin cytoskeleton 
disorganization (Shen et al., 2012). 
- Role in cell migration: 
The inhibition of RhoA signaling by blocking the 
interaction with its downstream effectors Rho-
associated kinase (ROCK) and mDia is required for 
both vaccinia morphogenesis and virus-induced cell 
motility (Valderrama et al., 2006). 
- Role in cell protrusion: 
RhoA activates focal adhesion kinase (FAK) 
signaling. RhoA has a role in the initial events of 
protrusion, whereas Rac1 and Cdc42 activate 
pathways implicated in reinforcement and 
stabilization of newly expanded protrusions 
(Machacek et al., 2009). 
- Role in exocytosis: 
RhoA is involved in Ca2+-dependent exocytosis at 
least partly through the reorganization of actin 
filaments (Komuro et al., 1996). This type of 
exocytosis is regulated by G12/G13 alpha through a 
Rho/Rho-associated kinase-dependent pathway 
(Yamaguchi et al., 2000). 
- Role in endocytosis: 
RhoA helps direct endocytosis in a variety of cell 
types (Lamaze et al., 1996; Khandelwal et al., 2010; 
Yu et al., 2010). RhoA is essential for clathrin- and 
caveolar- independent endocytosis (Sabharanjak et 
al., 2002). Treatment with the PI3K inhibitor 
(LY294002) or the FAK inhibitor (PF573228) 
suppresses compensatory endocytosis by inhibiting 
the activation of RhoA and then reducing the 
recruitment of ROCK (Khandelwal et al., 2010). 
- Role in cytokinesis: 
Cytokinesis requires actomyosin-based contraction. 
Inhibition of ROCK or citron kinase causes defects 
in cytokinesis resulting in multinucleate cells. 
Diaphanous-related formins (DRFs) are also 
implicated in this process, the DRF mDia1 localizes 
to the cleavage furrow during cytokinesis. DRFs 
could contribute to cytokinesis by stimulating local 
actin polymerization and/or by coordinating 
microtubules with actin filaments at the site of the 
contractile ring. RhoA signaling is controlled by the 
central spindle, a set of microtubule bundles that 
forms between the separating chromosomes. Thus, 
inactivation of Rac by centralspindlin functions in 
parallel with RhoA activation to drive contractile 
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ring constriction during cytokinesis (Canman et al., 
2008). 
- Role in cell cycle regulation: 
RhoA plays a pivotal role in G1 cell cycle 
progression, primarily through regulation of both 
cyclin D1 expression, and the levels of the cyclin-
dependent kinase inhibitors p21 and p27. Multiple 
pathways seem to link Rho proteins to the control of 
cyclin D1 levels. Many of these involve the 
activation of protein kinases, leading to the 
subsequent modulation of transcription factor 
activity. RhoA suppresses p21 levels in multiple 
normal and transformed cell lines. This effect 
appears to occur through a transcriptional 
mechanism but is independent of p53, a major 
transcriptional regulator of p21. RhoA plays an 
important role in determining the levels of p27 
through a pathway involving its effector, the Rho-
associated kinases. RhoA facilitates entry into S 
phase by degradation of the cyclin-dependent kinase 
inhibitor p27kip1 (Hirai et al., 1997). 
- Role in development: 
RhoA protein is required for processes involving cell 
migration in development including: neurite 
outgrowth, dorsal closure, bone formation, and 
myogenesis. Rho-loss of function is embryonically 
lethal in mouse development by E7. This is 
attributed to failure in gastrulation and an inability of 
cells to migrate. 
- Role in transcriptional control:  
The relationship between many of the cellular 
functions mediated by RhoA with transcriptional 
regulation has been described. RhoA modulates the 
activity of SRF, NF-kappaB, c/EBPb, Stat3, Stat5, 
FHL-2, PAX6, GATA-4, E2F, estrogen receptor 
alpha, estrogen receptor beta, CREB, and 
transcription factors that depend on the JNK and p38 
MAP kinase pathways. Substrates to these kinases 
include c-Jun, ELK, PEA3, ATF2, MEF2A, Max 
and CHOP/GADD153. 
- Role in cell proliferation: 
RhoA plays cell type-specific roles in the regulation 
of cell proliferation. RhoA plays critical roles in both 
early and late stages of B-cell development (Zhang 
et al., 2012). 
Mutations 
Note 
48 mutations have been described in the RhoA gene, 
according to the Catalogue of Somatic Mutations in 
Cancer (COSMIC) database.  
De novo mutations have been described in patients 
with Burkitt lymphoma: R5Q and I23R (Richter et 
al., 2012; Rohde et al., 2014); peripheral T-cell 
lymphoma: G17V, affecting the GTP-binding 
domain (Manso et al., 2014; Palomero et al., 2014; 
Sakata-Yanagimoto et al., 2014; Yoo et al., 2014); 
head and neck carcinoma: E40Q and Y42I, affecting 
the effector domain (Lawrence et al., 2014); diffuse-
type gastric carcinoma: R5Q, Y42I and G17V 
(Kakiuchi et al., 2014). 
Implicated in 
Breast carcinoma 
Oncogenesis 
RhoA protein levels were significantly increased in 
breast cancer compared with the corresponding 
normal tissue. Of particular note, protein levels of 
RhoA were barely detectable in normal mammary 
tissue, but were highly expressed in all breast tumors 
tested. Interestingly, RhoA protein levels correlated 
with increasing breast tumor grade. Moreover, 
decreased metastasis-free survival was predicted by 
RhoA and ROCK1 co-overexpression in breast cell 
lines and cancer tissues (Gilkes et al., 2014). On the 
other hand, blocking RhoA activity with the RhoA 
pathway specific inhibitor H-1152, or a RhoA 
specific siRNA, resulted in inhibition of invasive 
behavior in a triple-negative breast cancer cell line 
(Fagan-Solis et al., 2013). 
Ovarian carcinoma 
Oncogenesis 
Expression of RhoA is significantly increased in 
advanced ovarian carcinomas and also in the 
peritoneal disseminated lesions (Horiuchi et al., 
2008). The expression of the protein is further 
upregulated in tumors of stages III/IV when 
compared to those of stages I/II. Analysis of matched 
pairs of primary and metastatic lesions showed that 
expression of both RhoA mRNA was significantly 
higher in metastatic lesions of peritoneal 
dissemination than in the respective primary tumors. 
Testicular cancer 
Oncogenesis 
RhoA is involved in testicular germinal epithelial 
carcinogenesis and progression in testicular germ 
cell tumors (GCT) (Kamai et al., 2001). Protein 
expression of RhoA and its two major downstream 
effectors ROCK1 and ROCK2, was significantly 
higher in tumor tissue than in nontumor tissue from 
57 patients with GCT. The expression was greater in 
tumors of higher stages than lower stages, thus RhoA 
correlates with tumor stage and aggressiveness. 
Pelvic/ureteric cancer 
Oncogenesis 
Both mRNA and protein level of RhoA are elevated 
in pelvic/ureteric cancer with an increase in lymph 
node metastasis. The expression levels of RhoA 
were related to poorly differentiated grade and 
muscle invasion and associated with a shorter 
disease-free and overall survival. These findings 
suggest that RhoA is involved in the invasion and 
metastasis of upper urinary tract cancer, indicating 
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that RhoA may be a useful prognostic factor in this 
disease. 
Bladder cancer 
Oncogenesis 
A similar deregulation of RhoA is observed in 
bladder cancer.  
In this sense, RhoA and ROCK protein levels are 
elevated in tumors, again with higher expression in 
less differentiated tumors and metastatic lymph 
nodes compared to normal bladder.  
Interestingly, the levels of expression of RhoA and 
ROCK correlated positively with one another 
suggesting that the GTPase and its effector synergize 
to promote tumor progression. 
Lung tumors 
Oncogenesis 
Of the two major forms of lung cancer, small cell 
lung carcinoma (SCLC) and non-small cell lung 
carcinoma (NSCLC), the former has a greater 
metastatic potential.  
The expression and activation of RhoA is greater in 
SCLC than NSCLC cell lines. It has been observed 
that RhoA repress the expression of nitric oxide 
synthase-2 (NOS-2) in a lung cancer-derived cell 
line. Since NOS-2 activity is related to reduced 
proliferation, RhoA could be eliminating this 
antiproliferative signal in lung carcinogenesis. In 
addition, inhibition of RhoA by C3 exoenzyme or 
through ADP-ribosylation leads to an increase in 
cadherin-based adhesion and loss of motility of 
SCLC. RhoA overexpression and delta-catenin 
positive expression are consistently found in 
NSCLC, but not in normal lung tissue (Zhang et al., 
2014). 
Oesophageal squamous cell 
carcinoma (ESCC) 
Oncogenesis 
RhoA and RhoC proteins promote both cell 
proliferation and cell invasion of human ESCC cell 
lines in vitro and in vivo (Faried et al., 2006). There 
were significant correlations among RhoA 
overexpression and tumor-node-metastasis (TNM) 
clinical classification, lymphatic invasion, and 
blood-vessel invasion. The five-year survival rates 
for ESCC patients with RhoA overexpression were 
significantly lower than those in patients with RhoA 
under-expression. The expression of RhoA protein 
appeared to be correlated with tumour progression of 
ESCC. Patients with RhoA overexpression tended to 
have poor prognosis compared with patients with 
RhoA under-expression. 
Gastric cancer 
Oncogenesis 
RhoA was found frequently overexpressed in gastric 
cancer tissues compared with normal tissues, 
suggesting that RhoA may play a critical role in the 
carcinogenesis of this type of cancer. The 
interference of RhoA expression and/or activity 
could significantly inhibit the proliferation and 
tumorigenicity of gastric cancer cells and enhance 
the chemosensitivity to therapeutic agents such as 
Adriamycin and 5-fluorouracil. Inhibition of 
RhoA/ROCK signaling pathway promotes the 
apoptosis of gastric cancer cells (Xu et al., 2012). 
Recently, recurrent gain-of-function mutations of 
RhoA have been described in diffuse-type gastric 
carcinoma (Kakiuchi et al., 2014). 
Hepatocellular carcinoma (HCC) 
Oncogenesis 
Invasiveness of HCC is facilitated by the Rho/Rho-
kinase pathway and likely to be relevant to tumor 
progression. The Rho/Rho-kinase may be useful as a 
prognostic indicator and in the development of novel 
therapeutic strategies. The high expression of RhoA 
protein in HCC plays an important role in 
intrahepatic recurrence of patients who underwent a 
hepatectomy for HCC, and RhoA is a useful marker 
for predicting early recurrence in an early-stage 
HCC (Fukui et al., 2006). Overexpression of RhoA 
is associated with poor prognosis in HCC (Li et al., 
2006; Hu et al., 2013). 
Pancreatic tumor 
Oncogenesis 
Although overexpression of RhoA has not been 
detected in any pancreatic tumor tissue to date, it 
might nevertheless also be involved in pancreatic 
tumors. The progression of pancreatic tumors is 
partially controlled by the balance between Tiam1-
Rac1 and RhoA (Guo et al., 2013). Use of two 3-
hydroxy 3methylgultaryl coenzyme A (HMG-CoA) 
reductase inhibitors, fluvastatin and lovastatin 
inhibit human pancreatic cancer cell invasion and 
metastasis in a Rho-dependent manner. These 
inhibitors prevent the synthesis of cholesterol 
precursors necessary for proper membrane 
translocation of Rho protein. Also, BART plays a 
role in inhibiting cell invasion by regulating the 
activity of RhoA in pancreatic cancer cells (Taniuchi 
et al., 2011). 
Colorectal cancer 
Oncogenesis 
A high proportion of colon cancers overexpress 
RhoA and several aspects of colon tumor biology 
have been related to Rho GTPases.  
 
 
Leptin receptor and leptin-induced migration of 
colonic epithelial cancer cells is dependent on RhoA, 
since inhibition of the activity of the GTPase through 
introduction of dominant negative mutants 
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completely abolishes the invasive capacity of the 
tumor cells.  
On the other hand, GCF2 plays an important role in 
colorectal cancer metastasis by regulating RhoA-
induced cell adhesion, migration, and invasion 
(Ariake et al., 2012). 
Head and neck squamous cell 
carcinoma 
Oncogenesis 
RhoA, Rac2, and other proteins involved in initiating 
cell motility are promising clinical molecular 
markers for head and neck squamous cell cancer 
(Abraham et al., 2001). Mutations have affecting the 
effector domain (ED) have been described: these 
include five E40Q mutations and a single Y42I 
mutation, which alter the seventh and ninth amino 
acids, respectively, of the ED (Lawrence et al., 
2014). 
Peripheral T-cell lymphoma (PTCL) 
Oncogenesis 
New studies identify recurrent dominant-negative 
mutation of the RhoA GTPase gene in these 
lymphomas.  
In T-cell lines, expression of the G17V mutant 
reduced the formation of stress fibers in fibroblast, 
increased cell proliferation and cell migration. It has 
an important role in the pathogenesis of 
angioimmunoblastic t-cell lymphoma (AITL) and 
other subtypes of PTCL (Manso et al., 2014; 
Palomero et al., 2014; Sakata-Yanagimoto et al., 
2014; Yoo et al., 2014). 
Acute promyelocytic leukaemia (APL) 
Oncogenesis 
RhoA modulates functional and physical interaction 
between ROCK1 and Erk1/Erk2 in selenite-induced 
apoptosis of human leukaemia cells (Li et al., 2013). 
Pediatric Burkitt lymphoma 
Oncogenesis 
The mutation R5Q is detection in patients with 
pediatric Burkitt lymphoma. RhoA mutant induced 
inactivate the RhoA protein. Thus, deregulation of 
RhoA by mutation is a recurrent event in Burkitt 
lymphomagenesis in children (Rohde et al., 2014). 
Chronic myeloid leukemia (CML) 
Oncogenesis 
Higher expression of RhoA in CML could be 
responsible for increased proliferation of 
polymorphonuclear leukocytes (PMNL) cells (Molli 
et al., 2012). 
Prostate cancer 
Oncogenesis 
LPA stimulates RhoA and increased PC-3 prostate 
cancer cell invasion activity through an NF-kappaB-
dependent pathway (Hwang et al., 2006). Inhibition 
of RhoA activity induced senescence-like arrest in a 
human prostate carcinoma cell line (Park et al., 
2007). 
Osteosarcoma 
Oncogenesis 
Lipophilic statins induced membrane RhoA 
relocalization to the cytosol and inhibited RhoA 
activity, which resulted in decreased phospho-
p42/p44- mitogen-activated protein kinases 
(MAPKs) and Bcl-2 levels. Constitutively active 
RhoA rescued phospho-p42/p44-MAPKs and Bcl-2 
and abolished statin-induced apoptosis (Fromigué et 
al., 2006). 
Glioblastoma 
Oncogenesis 
Decreased RhoA activity occurred in correlation 
with increased glioma cell migration (Fortin Ensign 
et al., 2013). 
Cervical cancer 
Oncogenesis 
Overexpression of RhoA promotes the proliferation 
and migration of cervical cancer cells (Liu et al., 
2014). 
Squamous cell carcinoma of tongue 
(TSCC) 
Oncogenesis 
RhoA plays a significant role in TSCC progression 
by regulating cell migration and invasion through 
Wnt/β-catenin signaling pathway and cell 
proliferation through cell cycle regulation, 
respectively (Yan et al., 2014). 
Neurological disorders 
Oncogenesis 
RhoA protein was lower in the Alzheimer's disease 
(AD) brain hippocampus, reflecting loss of the 
membrane bound. Altered subcellular targeting of 
RhoA is related to neurodegeneration (Huesa et al., 
2010). In addition, an upregulation of RhoA 
immunoreactivity occurs in the brains of patients 
with intractable epilepsy (Yuan et al., 2010). Also, 
the Down syndrome critical region protein TTC3 
inhibits neuronal differentiation via RhoA and 
Citron kinase (Berto et al., 2007). 
Diabetic nephropathy 
Oncogenesis 
High glucose activates RhoA/Rho-kinase in 
mesangial cells (MC), leading to downstream AP-1 
activation and fibronectin induction. Inhibition of 
this pathway in vivo prevents the pathologic changes 
of diabetic nephropathy, supporting a potential role 
for inhibitors of RhoA/Rho in the treatment of 
diabetic renal disease (Peng et al., 2008). 
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Pregnancy 
Oncogenesis 
In the early stage pregnancy, up-regulation of RhoA 
induced by low oxygen conditions may play an 
important role in regulation of HIF-1α expression in 
trophoblast cells (Hayashi et al., 2005). 
Pulmonary hypertension (PH) 
Oncogenesis 
RhoA and Rho kinase activities are increased in PH 
(Guilluy et al., 2009). Inhibition of this pathway is 
involved in the beneficial effect of sildenafil on PH 
(Guilluy et al., 2005). 
Hypertension 
Oncogenesis 
RhoA signaling through Arhgef1 is central to the 
development of angiotensin II-dependent 
hypertension and identify Arhgef1 as a potential 
target for the treatment of hypertension (Guilluy et 
al., 2010). 
To be noted 
Note 
miR that target RHOA: RHOA is target of different 
microRNAs, according to the bioinformatic 
algorithms microRNA (microRNA.org). 
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